Intellia Therapeutics (38I) Financial Statements

13 Followers

Intellia Therapeutics Financial Overview

Intellia Therapeutics's market cap is currently €1.41B. The company's EPS TTM is €-3.83; its P/E ratio is -2.54; Intellia Therapeutics is scheduled to report earnings on April 30, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 67.67M	$ 57.88M	$ 36.27M	$ 52.12M	$ 33.05M
Gross Profit	$ 51.75M	$ 47.59M	$ 27.30M	$ 44.55M	$ 26.16M
Operating Income	$ -440.99M	$ -534.26M	$ -515.29M	$ -458.16M	$ -267.85M
EBITDA	$ -396.77M	$ -523.98M	$ -506.31M	$ -450.59M	$ -260.96M
Net Income	$ -412.69M	$ -519.02M	$ -481.19M	$ -474.19M	$ -267.89M
Balance Sheet
Cash & Short-Term Investments	$ 449.88M	$ 601.51M	$ 912.22M	$ 1.19B	$ 748.69M
Total Assets	$ 842.13M	$ 1.19B	$ 1.30B	$ 1.52B	$ 1.29B
Total Debt	$ 93.33M	$ 210.20M	$ 115.35M	$ 130.70M	$ 74.02M
Net Debt	$ -62.13M	$ 21.02M	$ -111.40M	$ -392.80M	$ -49.38M
Total Liabilities	$ 170.73M	$ 319.06M	$ 250.81M	$ 284.53M	$ 254.22M
Stockholders' Equity	$ 671.39M	$ 871.96M	$ 1.05B	$ 1.24B	$ 1.04B
Cash Flow
Free Cash Flow	$ -354.66M	$ -354.66M	$ -408.07M	$ -391.68M	$ -237.79M
Operating Cash Flow	$ -348.88M	$ -348.88M	$ -394.09M	$ -333.29M	$ -225.03M
Investing Cash Flow	$ 125.57M	$ 125.57M	$ -31.35M	$ 160.31M	$ -550.78M
Financing Cash Flow	$ 185.75M	$ 185.75M	$ 130.32M	$ 582.96M	$ 736.69M

Currency in USD

Intellia Therapeutics Earnings and Revenue History

Income Statement >

Intellia Therapeutics Debt to Assets

Balance Sheet >

Intellia Therapeutics Cash Flow

Cash Flow >

Intellia Therapeutics Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >